Diffuse optical spectroscopic imaging (DOSI) is used as an indicator of tumor blood volume quantified by tissue hemoglobin concentrations. We aimed to determine whether early changes in tumo'/> Near-Infrared Diffuse Optical Imaging for Early Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy: A Comparative Study Using 18F-FDG PET/CT
首页> 外文期刊>The Journal of Nuclear Medicine >Near-Infrared Diffuse Optical Imaging for Early Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy: A Comparative Study Using 18F-FDG PET/CT
【24h】

Near-Infrared Diffuse Optical Imaging for Early Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy: A Comparative Study Using 18F-FDG PET/CT

机译:近红外漫射光学成像在乳腺癌对新辅助化疗反应的早期预测中的应用:使用18F-FDG PET / CT的比较研究

获取原文
           

摘要

id="p-2">Diffuse optical spectroscopic imaging (DOSI) is used as an indicator of tumor blood volume quantified by tissue hemoglobin concentrations. We aimed to determine whether early changes in tumor total hemoglobin (tHb) concentration can predict a pathologic complete response (pCR) to neoadjuvant chemotherapy in patients with operable breast cancer, and we compared the predictive value of pCR between DOSI and 18F-FDG PET combined with CT. >Methods: Of the 100 patients enrolled, 84 patients were prospectively evaluated for primary objective analysis. Sixty-four of the patients underwent both sequential DOSI scans at baseline after their first and second chemotherapy courses and 18F-FDG PET/CT at baseline and after their second chemotherapy course. The mean tHb (tHbmean) concentration and SUVmax of the lesion were measured using DOSI and 18F-FDG PET/CT, respectively, and the percentage change in tHbmean (a??tHbmean) and change in SUVmax (a??SUVmax) were calculated. We compared the diagnostic performances of DOSI and 18F-FDG PET/CT for predicting pCR via the analysis of the receiver-operating-characteristic curves. >Results: pCR was achieved in 16 patients, and neoadjuvant chemotherapy caused a significant reduction of a??tHbmean in pCR compared with non-pCR after the 2 chemotherapy courses. When the tentative a??tHbmean cutoff values after the first and second courses were used, the ability to predict pCR was as follows: 81.2% sensitivity/47.0% specificity and 93.7% sensitivity/47.7% specificity, respectively. Comparison of the diagnostic performances of DOSI and 18F-FDG PET/CT revealed areas under the curve of 0.69 and 0.75 of a??tHbmean after the first and second courses, respectively, which were lower than those of a??SUVmax (0.90). >Conclusion: DOSI predicted pCR in patients with breast cancer with moderate accuracy. The diagnostic performance of DOSI was inferior to that of the early metabolic response as monitored by 18F-FDG PET/CT.
机译:id =“ p-2”>漫反射光谱成像(DOSI)用作通过组织血红蛋白浓度量化的肿瘤血容量的指标。我们旨在确定肿瘤总血红蛋白(tHb)浓度的早期变化是否可以预测可手术乳腺癌患者对新辅助化疗的病理完全缓解(pCR),并比较DOSI和 18 < / sup> F-FDG PET与CT结合。 >方法:前瞻性评估了100例患者中的84例患者的主要客观分析。 64例患者在第一次和第二次化疗后均在基线进行了连续DOSI扫描,并在基线和第二次化疗后均进行了 18 F-FDG PET / CT。使用DOSI和 18 F-FDG PET / CT分别测量病变的平均tHb(tHb 平均值)浓度和SUV max 浓度,和tHb mean (a ?? tHb mean )和SUV max (a ?? SUV max < / sub>)。我们通过分析接收器工作特性曲线,比较了DOSI和 18 F-FDG PET / CT对预测pCR的诊断性能。 >结果: 16例患者达到了pCR,新辅助化疗导致2个疗程后与非pCR相比,pCR的a ?? tHb mean 显着降低。当使用第一和第二疗程后的暂定a ?? tHb mean 临界值时,预测pCR的能力如下:敏感性为81.2%敏感性/47.0%和93.7%敏感性/47.7%特异性, 分别。比较DOSI和 18 F-FDG PET / CT的诊断性能,发现第一,第二疗程后a ?? tHb mean 在0.69和0.75曲线下的面积分别低于SUV max (0.90)。 >结论:DOSI预测乳腺癌患者的pCR具有中等准确性。通过 18 F-FDG PET / CT监测,DOSI的诊断性能不及早期代谢反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号